Brokerages forecast that NanoString Technologies, Inc. (NASDAQ:NSTG – Get Rating) will report earnings of ($0.67) per share for the current fiscal quarter, Zacks Investment Research reports. Three analysts have provided estimates for NanoString Technologies’ earnings. The highest EPS estimate is ($0.59) and the lowest is ($0.76). NanoString Technologies posted earnings per share of ($0.60) in the same quarter last year, which suggests a negative year over year growth rate of 11.7%. The business is expected to announce its next earnings results on Monday, January 1st.
According to Zacks, analysts expect that NanoString Technologies will report full year earnings of ($2.64) per share for the current financial year, with EPS estimates ranging from ($2.98) to ($2.38). For the next year, analysts anticipate that the firm will post earnings of ($2.07) per share, with EPS estimates ranging from ($2.70) to ($1.66). Zacks Investment Research’s earnings per share averages are an average based on a survey of sell-side research firms that follow NanoString Technologies.
NanoString Technologies (NASDAQ:NSTG – Get Rating) last posted its quarterly earnings results on Tuesday, May 10th. The biotechnology company reported ($0.86) EPS for the quarter, missing the consensus estimate of ($0.53) by ($0.33). The business had revenue of $31.08 million during the quarter, compared to analysts’ expectations of $30.95 million. NanoString Technologies had a negative net margin of 87.89% and a negative return on equity of 68.57%. The firm’s quarterly revenue was down 1.7% compared to the same quarter last year. During the same quarter last year, the firm earned ($0.62) EPS.
NanoString Technologies stock opened at $14.95 on Monday. The company has a debt-to-equity ratio of 1.55, a quick ratio of 7.11 and a current ratio of 7.81. The company has a market cap of $693.92 million, a price-to-earnings ratio of -5.36 and a beta of 1.98. NanoString Technologies has a 1 year low of $13.52 and a 1 year high of $70.40. The firm has a 50 day moving average price of $25.53 and a 200 day moving average price of $34.15.
In other news, SVP Joseph M. Beechem sold 2,968 shares of NanoString Technologies stock in a transaction that occurred on Tuesday, March 8th. The shares were sold at an average price of $33.06, for a total transaction of $98,122.08. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Also, CEO R Bradley Gray sold 8,625 shares of the business’s stock in a transaction on Tuesday, March 15th. The stock was sold at an average price of $27.81, for a total transaction of $239,861.25. The disclosure for this sale can be found here. Insiders sold 33,864 shares of company stock worth $1,054,146 over the last three months. 2.80% of the stock is currently owned by corporate insiders.
Several hedge funds and other institutional investors have recently made changes to their positions in the company. Pinebridge Investments L.P. purchased a new position in NanoString Technologies in the fourth quarter valued at about $30,000. Dark Forest Capital Management LP raised its position in shares of NanoString Technologies by 102.7% in the 3rd quarter. Dark Forest Capital Management LP now owns 1,267 shares of the biotechnology company’s stock valued at $61,000 after purchasing an additional 642 shares in the last quarter. Point72 Hong Kong Ltd boosted its stake in shares of NanoString Technologies by 449.7% during the 3rd quarter. Point72 Hong Kong Ltd now owns 1,979 shares of the biotechnology company’s stock valued at $95,000 after buying an additional 1,619 shares during the last quarter. Advisor Group Holdings Inc. grew its position in shares of NanoString Technologies by 15.0% during the fourth quarter. Advisor Group Holdings Inc. now owns 3,795 shares of the biotechnology company’s stock worth $160,000 after buying an additional 496 shares in the last quarter. Finally, Russell Investments Group Ltd. increased its stake in shares of NanoString Technologies by 33.6% in the third quarter. Russell Investments Group Ltd. now owns 4,400 shares of the biotechnology company’s stock worth $211,000 after buying an additional 1,107 shares during the last quarter.
About NanoString Technologies (Get Rating)
NanoString Technologies, Inc develops, manufactures, and sells tools for scientific and clinical research in the fields of genomics and proteomics in the Americas, Europe, the Middle East, and the Asia Pacific. The company offers nCounter Analysis System, an automated, multi-application, digital detection, and counting system.
- Get a free copy of the StockNews.com research report on NanoString Technologies (NSTG)
- MarketBeat Podcast: Options Trading As Easy As Trading Stocks
- The TJX Companies: It’s Not All Doom And Gloom In Retail
- Simply Good Foods Stock is Simply Looking Good Down Here
- Shoe Carnival’s Q1 Results Are No Joke, Shares Fall 15%
- Analog Devices Is Ready To Scale New Highs Despite Tech Wreck
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for NanoString Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NanoString Technologies and related companies with MarketBeat.com's FREE daily email newsletter.